Zacks Research Upgrades Armata Pharmaceuticals (NYSEAMERICAN:ARMP) to Hold

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Separately, HC Wainwright boosted their price target on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Price Performance

Shares of NYSEAMERICAN ARMP opened at $8.46 on Monday. Armata Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $16.34. The company’s 50-day moving average is $10.25 and its 200 day moving average is $8.20. The stock has a market capitalization of $310.57 million, a P/E ratio of -1.09 and a beta of 1.31.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million. Research analysts anticipate that Armata Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On Armata Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ARMP. SeaCrest Wealth Management LLC grew its holdings in Armata Pharmaceuticals by 17.3% in the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after purchasing an additional 6,034 shares during the period. Geode Capital Management LLC grew its holdings in Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock worth $690,000 after purchasing an additional 5,342 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $284,000. Renaissance Technologies LLC grew its holdings in shares of Armata Pharmaceuticals by 65.9% during the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock valued at $430,000 after buying an additional 27,200 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $108,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.